文献速递血栓与止血

FVIII特异性人嵌合抗原受体调节性T细胞抑制对FVIII的T细胞和B细胞应答

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.
PubMed 文献 · Blood · 2016-11-15

血友病A患者接受FVIII替代治疗后常因缺乏免疫耐受产生抑制性抗体,亟需ITI以外的耐受性疗法。本研究利用合成噬菌体展示库来源的FVIII特异性scFv构建ANS8嵌合抗原受体(CAR),转导的ANS8 CAR Treg在体外可抑制针对不同FVIII结构域的FVIII特异性T效应细胞增殖,并抑制FVIII敲除小鼠脾细胞对FVIII的回忆抗体应答(体外和体内)。结论认为CAR转导Treg是未来治疗伴抑制物血友病A患者有前景的耐受性方法。

要点

  • ANS8 CAR由合成噬菌体展示库来源的FVIII特异性scFv构建,靶向A2结构域。
  • ANS8 CAR Treg在体外抑制针对不同FVIII结构域的FVIII特异性T效应细胞增殖,提示旁观者抑制。
  • ANS8 CAR Treg在体外和体内均抑制FVIII敲除小鼠脾细胞对FVIII的回忆抗体应答。

核心结论

  • CAR转导的Treg是未来治疗伴抑制物血友病A患者有前景的耐受性方法。

研究设计与样本

  • 研究构建FVIII特异性嵌合抗原受体(ANS8 CAR),使用来源于合成噬菌体展示库的FVIII特异性scFv。
  • 将ANS8 CAR转导入T细胞和Treg,在体外评估对FVIII的增殖与抑制功能。
  • 在体外和体内评估ANS8 CAR Treg对FVIII敲除小鼠脾细胞回忆抗体应答的抑制作用。

主要发现

  • 转导的ANS8 CAR T细胞特异性针对A2结构域,在体外响应FVIII而增殖。
  • ANS8 CAR Treg在体外能抑制针对不同FVIII结构域的FVIII特异性T效应细胞增殖。
  • ANS8 CAR Treg在体外和体内均能抑制FVIII敲除小鼠脾细胞对FVIII的回忆抗体应答。

临床怎么用

  • 原文结论认为CAR转导Treg是未来治疗伴抑制物血友病A患者有前景的耐受性方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Replacement therapy with factor VIII (FVIII) is used in patients with hemophilia A for treatment of bleeding episodes or for prophylaxis. A common and serious problem with this therapy is the patient's immune response to FVIII, because of a lack of tolerance, leading to the formation of inhibitory antibodies. Development of tolerogenic therapies, other than standard immune tolerance induction (ITI), is an unmet goal. We previously generated engineered antigen-specific regulatory T cells (Tregs), created by transduction of a recombinant T-cell receptor (TCR) isolated from a hemophilia A subject's T-cell clone. The resulting engineered T cells suppressed both T- and B-cell effector responses to FVIII. In this study, we have engineered an FVIII-specific chimeric antigen receptor (ANS8 CAR) using a FVIII-specific scFv derived from a synthetic phage display library. Transduced ANS8 CAR T cells specific for the A2 domain proliferated in response to FVIII and ANS8 CAR Tregs were able to suppress the proliferation of FVIII-specific T-effector cells with specificity for a different FVIII domain in vitro. These data suggest that engineered cells are able to promote bystander suppression. Importantly, ANS8 CAR-transduced Tregs also were able to suppress the recall antibody response of murine splenocytes from FVIII knockout mice to FVIII in vitro and in vivo. In conclusion, CAR-transduced Tregs are a promising approach for future tolerogenic treatment of hemophilia A patients with inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yoon J, Schmidt A, Zhang AH, et al. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood. 2016. PMID: 28064157. doi:10.1182/blood-2016-07-727834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。